Introduction
Dabigatran etexilate (dabigatran) is a novel oral thrombin inhibitor approved for the risk reduction of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) [Weimar et al. 2012] . The approval of this new oral anticoagulant (NOAC) was based on the large phase III clinical trial of stroke prevention in AF, the [Legrand et al. 2011; Bene et al. 2012] . Moreover, there was a trend towards a higher incidence of myocardial infarction (MI) in patients treated with dabigatran in the RE-LY study Diener et al. 2010] . Experts worldwide recommend caution with the use of dabigatran in clinical practice given a number of unresolved issues including lack of effective laboratory monitoring, lack of antidote as well as safety concerns about use in elderly and in patients with renal insufficiency [Stollberger and Finsterer, 2012a] .
The aim of the present multicenter study was to prospectively evaluate the safety, efficacy and adherence to dabigatran for secondary stroke prevention in an 'everyday clinical practice' setting.
Methods
Consecutive AF patients with ischemic stroke (IS) or transient ischemic attack (TIA) were treated with dabigatran for secondary stroke prevention according to American Heart Association (AHA) recommendations [Wann et al. 2011] at five tertiary care stroke centers (Department of Neurology, Attikon Hospital, Athens, Greece; Department of Neurology, Alexandroupolis, Greece; Department of Neurology, Singapore, Singapore; Department of Neurology, Bochum, Germany; and Comprehensive Stroke Research Center, Birmingham, Alabama, USA) during a 2-year study period (May 2011 to May 2013). Dabigatran was initiated early after ischemic symptom onset and during patients' hospital stay.
All patients were included in a computerized databank. Their demographic characteristics, vascular risk factors and secondary prevention therapies during hospitalization and after discharge were documented as previously described in similar studies by our international collaborative group [Tsivgoulis et al. 2010 [Tsivgoulis et al. , 2012 Zhao et al. 2011] . Stroke risk stratification was performed in AF patients using the CHADS 2 (congestive heart failure, hypertension, diabetes mellitus, age >75 years, prior stroke or TIA) score [Gage et al. 2004] . AF patients were prospectively followed up at outpatient stroke clinics of our respective institutions and were clinically re-evaluated at regular 3-month intervals during the follow-up period by an attending neurologist as previously described [Tsivgoulis et al. 2010] . During the follow-up period outcomes (IS, TIA, systemic embolism, pulmonary embolism, MI) were documented according to RE-LY methodology ]. The primary safety outcome was major hemorrhage, defined according to RE-LY criteria as a reduction in the hemoglobin level of at least 20 g per liter, transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ ]. Secondary safety outcomes included all other bleeding events other than major hemorrhage and were subsequently classified as minor bleedings.
Statistical analyses
Continuous parametric and nonparametric data are presented as mean ± standard deviation (SD) or as median (range) respectively. Noncontinuous variables are presented as percentages. The Statistical Package for Social Science (SPSS Inc., version 13.0 for Windows) was used for statistical analyses.
Results
We prospectively enrolled 78 AF patients (63 with IS and 15 with TIA) with a mean age of 71 ± 9 years (54% men, 46% women). The median CHADS 2 -score was 4 (range 2-5). Approximately a quarter of patients were treated with dabigatran dose of 150 mg twice daily (bid) (26%), while the remaining AF patients (n = 58; 74%) received a dabigatran dose of 110 mg bid. Baseline characteristics and stroke risk factors are shown in Table 1 .
The study population was prospectively followed for a mean follow-up period of 7 ± 5 months (range 1-18). The outcome events of interest during the follow-up period are presented in Table 2 . There were no cases of IS, TIA, systemic embolism or myocardial infarction. There were two major adverse events (2.6%) with two patients presenting with major lower gastrointestinal hemorrhage. Both patients with major lower gastrointestinal hemorrhage required hospitalization and multiple transfusions to be stabilized. Dabigatran was discontinued and, after 1 month, patients received oral anticoagulation with coumadin. We documented two minor adverse events (2.6%) in another two patients (one case of rectal bleeding and one case of hematuria). Creatinine clearance was >50 ml/min/1.73 m 2 in the four patients who presented with minor or major bleeding events. Two out of the four patients with adverse events (one major and one minor bleeding) were treated with dabigatran 150 mg bid, while the remaining two (one major and one minor bleeding) received 110 mg of dabigatran bid. No events of intracranial bleeding were reported.
In our study cohort, treatment with dabigatran was terminated in 20 patients (26%); in half of these patients this decision was made due to the high treatment cost. Other reasons for dabigatran discontinuation were the aforementioned side effects in three patients (15%) and patient's noncompliance in another three cases (15%). Dyspepsia, bloating and flatulence were the side effects reported in two out of three patients who discontinued dabigatran. Finally, dabigatran was substituted with coumadin in four patients (20%) by primary care physicians, without any of these patients experiencing any side effects and without any reason provided by the primary care physician (Table 3) . Finally, in two patients who discontinued dabigatran (10% of cases with dabigatran discontinuation) an embolic event (one case of IS and one case of systemic embolism) occurred when coumadin was substituted for dabigatran.
Discussion
Our pilot data indicate that dabigatran appears to be safe for secondary stroke prevention during the first year of implementation of this therapy during hospitalization for acute cerebral ischemia. However, high cost may lead to early discontinuation and therefore limit the long-term treatment of AF patients with dabigatran. Notably, all bleeding adverse events (both minor and major) affected the gastrointestinal system, while we documented no cases of recurrent stroke or intracranial bleeding in AF patients treated with dabigatran.
Comparing the baseline characteristics of our patients with those from a RE-LY trial subgroup including patients with a history of IS or TIA [Diener et al. 2010] , we observed almost the same mean age (71 versus 70 years old) and a similar mean CHADS 2 score (4 in our study versus 3 or more in 89.6% of the RELY subgroup). However, our study represented fewer men (54% versus 64%) and more patients received a lower dabigatran dose (110 mg) in our cohort (74% versus 50%). Another notable difference is that our study was not randomized unlike RE-LY.
Only one case of pulmonary embolism, two cases of major hemorrhages and two cases of minor bleeding were reported during the follow-up period in our study. The annual rates of major bleeding were lower in our cohort (2.6%) compared with the RE-LY secondary prevention subgroup (2.7% for 110 mg bid dose and 4.2% for 150 mg bid dose) [Diener et al. 2010 ]. These findings are in line with a recently published population-based cohort study from Denmark [Larsen et al. 2013 ]. More specifically, stroke and systemic embolism incidences were not significantly different between dabigatran-and warfarin-treated patients, while patients treated with 110 mg dabigatran -similarly to RE-LY -had lower gastrointestinal bleeding rates compared with warfarin treated patients. The rates of overall mortality, intracranial bleeding, pulmonary embolism and MI -contrary to RE-LY -were lower in our dabigatran treated patients. Markedly, the major bleeding event rates (2.2% for 150 mg bid dose and 2.8% for 110 mg bid dose) were very close to our reported rate of major bleeding events (2.6%). The recently reported observations from the US Food and Drug Administration sponsored Mini-Sentinel distributed database provide further reassurance that bleeding rates associated with dabigatran are not higher than warfarin [Southworth et al. 2013] . Similarly, the use of dabigatran in the prevention of stroke and systemic embolism in patients with AF was found to be associated with an increase of 58% in the risk for gastrointestinal bleeding in a recent systematic review and meta-analysis [Holster et al. 2013] .
Emerging case reports have indicated that older age [Legrand et al. 2011; Bene et al. 2012; Husari et al. 2013] , lower [Legrand et al. 2011] or higher body weight [Wychowski and Kouides, 2012] and renal insufficiency [Legrand et al. 2011; Bene et al. 2012; Wychowski and Kouides, 2012] may increase the risk of bleeding in AF patients treated with dabigatran (Table 4 ). Age-related risk of bleeding with dabigatran is mainly associated with the concurrent renal impairment, although age alone can also be considered a separate risk factor due to the increased drug bioavailability and the concomitant bleeding complications [Stollberger and Finsterer, 2012b] . Patients with severe renal insufficiency [creatinine clearance (CrCl) < 30 ml/min/1.73 m 2 ] were excluded by study design in the RE-LY trial, while patients with a CrCl = 30-49 ml/min/1.73 m 2 were also underrepresented (19% of the total study population). Similarly, only 0.02% of the patients had a bodyweight lower than 50 kg and only 0.17% weighted more than 100 kg in the RE-LY study population Jacobs and Stressman, 2011] . Therefore, clinicians should be cautious when administering dabigatran in these specific AF patient subgroups. Of note though, none of the two patients with major bleeds events in our cohort were underweight or overweight nor did they present with impaired CrCl at the time of the bleeding event. Moreover, it should be kept in mind that there is a greater likelihood of reporting bleeding events in patients receiving dabigatran, due to the novelty of the treatment, than in ones receiving the time-tested warfarin [Southworth et al. 2013] .
A retrospective review of the medical charts uncovered 44 bleeding episodes (27% of them major) in patients treated with dabigatran during the initial 2-month period after the release of the drug in Australia and New Zealand. Rectal bleeding was the most common bleeding complication in 19 of the aforementioned patients (44), while severe intracranial bleeding was reported in only one patient (0.02%). Four major factors were found to contribute to a bleeding episode: prescriber error (25%); moderate or severe renal impairment (58%); age over 80 years (67%); and bodyweight less than 60 kg (50%) [Harper et al. 2012] . We also documented lower gastrointestinal bleeding events as the most common bleeding complication in our cohort and our data, combined with the recent literature (Table 4) , highlight the need for extra caution to uncover a potential history of rectal or colon or diverticulum bleeding prior to administering dabigatran in AF patients.
Interestingly, the main reason which was taken into account for dabigatran discontinuation in our cohort included high treatment cost and was not associated with either experienced side effects or patient's noncompliance. The high price of dabigatran may pose a serious barrier for not using it as a chronic treatment in patients with nonvalvular AF, leading to dabigatran substitution with much cheaper warfarin. However, according to the results from a cost-effectiveness study by Freeman and colleagues, dabigatran may be a cost-effective alternative to warfarin in patients over 65 years old with nonvalvular AF at high risk for stroke (CHADS 2 score >1 or equivalent). The cost-effectiveness largely depends on the pricing of both drugs and the pricing of coagulation tests for warfarin monitoring in each country [Freeman et al. 2011] . Thus, it is important for physicians to ensure that patients can afford dabigatran before prescribing it. For patients with AF who cannot afford dabigatran, warfarin will remain a relatively inexpensive and effective alternative [Alberts et al. 2012] . The lack of an antidote was another reason that prompted treating physicians to discontinue dabigatran in patients experiencing minor bleeding events. However, it should be noted that there are promising data from a phase I/II study indicating the feasibility of complete reversal of anticoagulant effects of dabigatran using a fragment of an antibody against dabigatran [Glund et al. 2013] .
Certain limitations of the present study need to be acknowledged including the limited sample size and the short duration of the follow-up period. Moreover, there was no central adjudication of safety endpoints that were reported by local investigators. Finally, we have no control group with which to compare the rate of safety endpoints that were observed in the present cohort. It should be noted, however, that the aim of the present multicenter study was to prospectively evaluate the safety, efficacy and adherence to dabigatran for secondary stroke prevention in an 'everyday clinical practice' setting, since there is limited postmarketing experience with this novel oral anticoagulant.
In conclusion, our pilot study provides reassurance regarding the safety of dabigatran for secondary stroke prevention, but caution against its early discontinuation due to the drug's high cost.
Clinicians should keep in mind that lower gastrointestinal bleeding events more commonly complicate dabigatran use when compared with intracranial hemorrhages, which constitute however the most feared and life-threatening complications. These findings underscore the importance of additional long-term data collection on the safety, efficacy and adherence to dabigatran given the fact that most AF patients with stroke require lifelong oral anticoagulation [Banerjee et al. 2011] .
Funding
This research received no specific grant from any funding agency in the public, commercial, or notfor-profit sectors.
Financial disclosures
G. T. has been supported by European Regional Development Fund -Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123). 
